ROYALTY PHARMA
Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma does not discover, develop, manufacture or market products. Instead, the Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with research instit... utions, inventors and biotechnology & pharmaceutical companies since 1996, and now owns royalty interests in forty four approved and marketed biopharmaceutical products and seven products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency ("EMA”).
ROYALTY PHARMA
Social Links:
Industry:
Biotechnology Manufacturing Pharmaceutical
Founded:
1996-01-01
Status:
Active
Contact:
212-883-0200
Total Funding:
0
Technology used in webpage:
SPF Google Font API Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS GoDaddy DNS Apache 2.4
Similar Organizations
Welmedix Consumer Healthcare
Welmedix Consumer Healthcare develops and markets pharmaceutical products.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Onspira Therapeutics
Onspira Therapeutics operates as a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-11-07 | Eisai | Eisai acquired by Royalty Pharma | 330 M USD |
Investors List
General Atlantic
General Atlantic investment in Private Equity Round - Royalty Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-01 | Cytokinetics | Royalty Pharma investment in Post-IPO Debt - Cytokinetics | 450 M USD |
| 2022-05-18 | ApiJect | Royalty Pharma investment in Private Equity Round - ApiJect | 111 M USD |
| 2021-11-22 | BioCryst Pharmaceuticals | Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals | 350 M USD |
| 2020-12-07 | BioCryst Pharmaceuticals | Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals | 325 M USD |
| 2019-11-07 | Epizyme | Royalty Pharma investment in Post-IPO Equity - Epizyme | 100 M USD |